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SUMMARY
Granulomatous polyangitis (Wegener granulomatosis): clinical findings and results of long-term follow-up 
Introduction: To evaluate long-term outcome of patients with granulomatous polyangitis (GPA) followed up in a tertiary university 
hospital. 
Patients and Methods: We reviewed medical records of 22 patients with GPA diagnosis confirmed by tissue biopsies between 2004 and 
2014.
Results: The mean time from the onset of symptoms to diagnosis was 7.8 ± 12.3 months [interquartile range (IR)= 4.0]. The most 
commonly involved organs were the upper respiratory tract (URT) (72.7%), lower respiratory tract (81.8%) and kidneys (72.7%). 
URT involvement indicated good prognosis (p= 0.046). Survival in the patients with and without URT involvement was 124.6 ± 
6.9 months and 59.7 ± 22.9 months, respectively. End-stage renal 
failure (ESRF) requiring dilaysis and cardiac involvement were 
associated with mortality (p= 0.022 and p= 0.026, respectively). 
Of the 12 dialysis-dependent patients at diagnosis, 11 survived > 
3 months and seven regained renal function permanently. Dialysis 
dependency was significantly lower in patients who received 
plasmapheresis (p= 0.047). Overall mortality rate was 18% 
(4/22). Mean survival was 55.9 ± 42.8 months (IR= 84.0).
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INTRODUCTION
Wegener granulomatosis was first defined in 1936 by 
Friedrich Wegener but has been known as granuloma-
tous polyangitis (GPA) since 2011. It is a form of vascu-
litis that is associated with antineutrophilic cytoplasmic 
antibody (ANCA). Clinical signs of GPA are variable and 
may involve many organs; most commonly, the upper 
respiratory truct (URT), lower respiratory tract, and kid-
neys. Although its etiology remains unclear, it is thought 
to occur due to infectious, environmental, chemical, 
toxic and pharmacological stimulation in individuals 
who are prone to autoimmune diseases. The diagnosis 
is based on clinical findings, ANCA positivity, and 
appropriate histopathological findings (1).
Prompt diagnosis and treatment are important in pre-
venting mortality and/or permanent organ damage. 
Remission occurs in 85%-90% of treated patients (2). 
Despite current advances in diagnosis and treatment, 
relapse and refractory disease remain as challenges 
(3). Relapse rate within 5 years is ~50% (4).
The present study aimed to investigate clinical and 
laboratory characteristics of GPA in patients followed 
for 11 years in a tertiary university hospital, as well as 
the results of long-term follow-up and survival, and 
related factors.
MATERIALS and METHODS  
We enrolled 22 patients who were diagnosed with 
GPA based on the American Rheumatology College 
(ACR) 1990 criteria between 2004 and 2014 in 
Baskent University Adana Dr. Turgut Noyan Teaching 
and Medical Research Center. Patient information 
was obtained from the medical records, which 
included all necessary clinical, laboratory and patho-
logical data. The diagnosis was confirmed by tissue 
biopsy in all patients.
The cases were evaluated in terms of demographic char-
acteristics, clinical and laboratory findings, time to 
diagnosis, diagnostic methods, sites of organ involve-
ment, Birmingham Vascular Activity Score (BVAS) and 
Vascular Damage Index (VDI) at diagnosis, treatment 
approaches, follow-up duration, and long-term disease 
progression. ANCA tests were performed in the same 
laboratory using indirect immunofluorescence.
A follow-up protocol was used in 21 patients. The 
remaining one patient died at diagnosis before the 
treatment is started. Patients received baseline thera-
py as inpatients. After achieving complete or partial 
remission, they were regularly followed in outpatient 
clinics. First-line treatment consisted of combined 
methylprednisolone and cyclophosphamide (CYC). 
Conclusion: Diagnosis of GPA may be delayed by the nonspecific nature of its symptoms. URT involvement was associated with good 
prognosis, whereas cardiac involvement and ESRF requiring dialysis were associated with poor outcome. Plasmapheresis may increase 
the rate of renal recovery in the patients with ESRF requiring dialysis.
Key words: Granulomatosis polyangitis, outcome, vasculitis, Wegener granulomatosis
ÖZET
Granülomatöz polianjit (Wegener granülomatozis): Klinik bulgular ve uzun dönem izlem sonuçları 
Giriş: Üçüncü basamak bir üniversite hastanesinde granülomatöz polianjit (GPA) tanılı hastaların uzun dönem izlem sonuçlarının 
değerlendirilmesi.
Materyal ve Metod: Hastanemizde 2004-2014 tarihleri arasında, tanısı doku biyopsileri ile doğrulanmış 22 GPA’lı hastanın medikal 
kayıtları incelendi. 
Bulgular: Semptomların başlangıcından tanıya kadar geçen süre 7.8 ± 12.3 ay [interquartile range (IR)= 4.0] olarak bulundu. En sık 
tutulan organlar üst solunum yolu (ÜSY) (%72.7), alt solunum yolu (%81.8) ve böbreklerdi (%72.7).  ÜSY tutulumu iyi prognoz gös-
tergesiydi (p= 0.046). Sağkalım süresi ÜSY tutulumu olan ve olmayan hastalarda sırasıyla 124.6 ± 6.9 ay ve 59.7 ± 22.9 aydı. Diyaliz 
gerektiren son dönem böbrek yetmezliği (SDBY) ve kardiyak tutulum mortalite ile ilişkili bulundu (sırasıyla p= 0.022 ve p= 0.026). Tanı 
sırasında diyalize bağımlı 12 hastanın 11’i 3 aydan uzun süre yaşadı ve bunların 7’sinde böbrek fonksiyonları kalıcı olarak düzeldi. 
Plazmaferez uygulanan hastalarda diyaliz bağımlılığı anlamlı olarak düşüktü (p= 0.047). Toplam mortalite oranı %18 (4/22) olarak 
bulundu. Ortalama sağkalım 55.9 ± 42.8 aydı (IR= 84.0).
Sonuç: Hastalığın nonspesifik semptomları nedeniyle GPA tanısında gecikmeler yaşanabilmektedir. Çalışmamızda ÜSY tutulumu iyi 
prognoz göstergesi olarak bulunurken, kardiyak tutulum ve diyaliz gerektiren SDBY kötü prognoz ile ilişkili bulundu. Plazmaferez 
diyaliz gerektiren SDBY’li hastalarda iyileşme hızını artırabilir. 
Anahtar kelimeler: Granülomatöz polianjit, sonuçlar, vaskülit, Wegener granülomatozisi
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Pulse methylprednisolone therapy was started at a 
dose of 500 mg/day for 3-5 days depending on disease 
activity. Subsequently, treatment continued with pred-
nisolone at a dose of 1 mg/kg/day. It was targeted to 
reduce corticosteroid dose to 15-20 mg/day within 3-4 
months. Simultaneously, intravenous CYC was com-
menced at a dose of 500 mg/day at 2-week intervals 
for the first 3 months and then continued every 4-6 
weeks depending on disease activity. After 2011, 
patients with refractory disease and serious disease 
activity received an additional 1 g rituximab (RTX) (an 
anti-CD20 monoclonal antibody) every 6 months on 
two occasions at 2-week intervals. Plasmapheresis was 
performed 7-10 times in cases with serious renal injury 
and alveolar hemorrhage. Maintenance therapy was 
started within 12-18 months in the patients with remis-
sion. This consisted of azathioprine (AZA), methotrex-
ate (MTX) or mycophenolate mofetil (MMF). The dose 
of methylprednisolone was increased in the patients 
that developed relapse and combined with CYC or 
RTX; frequency of administration was increased in the 
patients already receiving CYC. All patients that 
received CYC and RTX also received trimethoprim-
sulfamethoxazole therapy 3 days a week for prophy-
laxis of Pneumocystis jirovecii infection.
Statistical Analysis 
Statistical analysis was performed using SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA). Continuous vari-
ables were presented as mean ± standard deviation 
[p> 0.05 in Kolmogorov-Smirnov or Shapiro-Wilk test 
(n< 30)] if they showed a normal distribution, where-
as they were presented as median if they were not 
distributed normally. Continuous variables were 
compared using Mann-Whitney U test depending on 
non-parametric values. The categorical variables 
were compared between the groups using the chi-
square test or Fisher’s exact test. The level of statistical 
significance was predetermined as p< 0.05.
RESULTS
Baseline data at diagnosis for 22 GPA patients are 
shown in Table 1. There were nine female and 13 
male patients, with a mean age at diagnosis of 47.0 ± 
10.9 (IR= 17.0) years. The longest follow-up period 
was 132 months and the last patient was enrolled 2 
months before the completion of study. The mean 
time to diagnosis was 7.8 ± 12.3 (IR= 4.0) months 
and the mean follow-up duration was 42.9 ± 39.9 
(IR= 74.0) months. The most commonly involved sites 
were the lungs (18, 81.8%), URT (16, 72.7%) and 
kidneys (16, 72.7%). There were nine cases with the 
classical triad of GPA: combination of URT and lower 
respiratory tract and renal involvement. Six cases 
developed alveolar hemorrhage. Of the 12 patients 
that required dialysis at baseline, 11 survived > 3 
months and 7 discontinued dialysis over the course of 
follow-up. Although one patient died shortly after 
hemodialysis was started (day 15 of diagnosis), hemo-
dialysis was continued throughout the follow-up peri-
od in the remaining four patients (3 hemodialysis, 1 
peritoneal dialysis). Cardiac involvement was seen in 
two cases as mitral valve disease and heart failure. 
With regard to the baseline laboratory analysis, 
erythrocyte sedimentation rate (ESR), creatinine val-
ues and creatinine clearances were 93.7 ± 26.8 
(IR= 35.0) mm/s and 4.5 ± 3.8 (IR= 7.02) mg/dL, and 
382.7 ± 343.8 (IR= 620.5), respectively. No significant 
Table 1. Demographic, clinical and serological chanracteristics 
of the patients at diagnosis
Parameters Values 
Sex (F/M) 9/13
Age at diagnosis (years) 47.0 ± 10.9 (IR= 17.0)
Time to the diagnosis (months) 7.8 ± 12.3 (4.0)
Follow-up duration (months) 42.9 ± 39.9 (IR= 74.0)
Survival (months) 55.9 ± 42.8 (IR= 84.0)
Constitutional symptoms, n (%) 21 (95.5)
Lungs, n (%) 18 (81.8)
Upper respiratory tract, n (%) 16 (72.7)
Kidneys, n (%) 16 (72.7)
Eyes, n (%) 4 (18.2)
Mucous membrane, n (%) 4 (18.2)
Skin, n (%) 4 (18.2)
Musculoskeletal, n (%) 13 (59.1)
Nervous system, n (%) 4 (18.2)
Cardiovascular system, n (%) 2 (9.1)
Breasts, n (%) 1 (4.5)
Gastrointestinal system, n (%) 2 (9.1)
Alveolar hemorrhage, n (%) 6 (27.3)
Renal failure, n (%) 12 (54.5)
Upper respiratory tract +
lungs + kidneys, n (%)
9 (40.9)
ESR, mm/h 93 ± 26 (IR= 35.0)
Creatinine, mg/dL 4.5 ± 3.8 (IR= 7.02)
Creatinine clearance 382.7 ± 343.8 (IR= 620.5)
c-ANCA positivity, n (%) 19 (86.4)
BVAS score 19.3 ± 6.1 (IR= 9.0)
VDI score 3.9 ± 2.0 (IR= 3.0)
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correlation was demonstrated between these labora-
tory parameters and mortality. Cytoplasmic-ANCA 
(c-ANCA) was positive in 19 patients, whereas perinu-
clear-ANCA (p-ANCA) was positive in five. p-ANCA 
was positive in all three cases with negative c-ANCA 
results. The mean BVAS score was 19.3 ± 6.1 (IR= 9.0), 
and no correlation was shown with mortality. The 
mean VDI score was 3.9 ± 2.0 (IR= 3.0), and there was 
no significant correlation between surviving and 
deceased patients (3.6 ± 2.0 and 5.5 ± 1.0, respec-
tively; p< 0.081).
No radiological pulmonary pathology was detected 
in four cases. The most common radiological finding 
was cavitary (7 cases)/non-cavitary (7 cases) nodular 
mass lesions. Ground glass opacity was observed in 
eight and consolidation was observed in four cases, 
whereas pleural thickening was observed in one. 
Four patients (18.2%) stopped follow-up visits. 
Information that these cases were alive was obtained 
via telephone call or from the central recording sys-
tem. Of the 17 patients that continued follow-up 
over the course of their treatment, eight completed 
follow-up without relapse. Relapse developed in 
nine cases [(53%); in the lungs in 5 patients and in 
the kidneys in 4]. Refractory disease was seen in 
one case. 
Tretament regimens of 21 patients are demonstrated 
in Table 2. Initially, all patients received methylpred-
nisolone and CYC. Complete remission could not be 
achieved in four patients. These patients received 
RTX in addition to CYC. No adverse events that 
require discontinuation of intravenous CYC adminis-
tration occurred over the course of treatment. None 
of the patients developed hemorrhagic cystitis, blad-
der carcinoma, severe immunesuppression or leuko-
penia over the course of follow-up. Plasmapheresis 
as induction therapy was performed in six patients. 
Of these patients, four had end-stage renal failure 
(ESRF) requiring dialysis, one had ESRF requiring 
dialysis together with alveolar hemorrhage, and one 
had only alveolar hemorrhage. It was observed that 
all the five patients that underwent plasmapheresis 
regained renal functions, and remained dialysis free 
for their follow-up period. Maintenance therapy 
including AZA (15 patients, 2-2.5 mg/kg/day), MTX 
(1 patient, 15 mg/week) or MMF (1 patient, 2 g/day) 
was started in the patients that developed remission 
within 12-18 months. Relapse occurred in nine 
patients. Either the dose of methylprednisolone was 
increased or pulse IV methylprednisolone (500-1000 
mg/day, 3-5 days) therapy was administered in these 
patients. They also received CYC (7 patients) or RTX 
(2 patients) in addition to methylprednisolone. 
During follow-up, one case developed chronic lym-
phocytic leukemia together with non-Hodgkin’s lym-
phoma, one developed pulmonary tuberculosis, and 
another developed P. jirovecii pneumonia. Hepatitis 
B reactivation occurred in one patient receiving RTX. 
One case (with refractory disease) underwent surgery 
for pneumothorax and prolonged air leak. A total of 
four cases died. Cause of death was sepsis in two 
cases (the source was wound site infection in one 
and peritonitis in the other), whereas the remaining 
two cases died from GPA. One of these patients, who 
died on day 15 of hospitalization, had ESRF requiring 
dialysis, alveolar hemorrhage with pulmonary 
involvement, and URT involvement. The other case 
died due to recurrent disease. 
No significant relation was determined between 
renal or pulmonary involvement and prognosis. URT 
involvement indicated good prognosis (Figure 1A); 
however, ESRF requiring hemodialysis (Figure 1B) 
and cardiac involvement showed a significant cor-
Table 2. Treatment regimen of 21 patients with granulomatous with polyangitis
Induction of remission
n (%)
Maintenance therapy
n (%)
Relapse therapy
n (%)
CYC (IV); 500 mg/day at 2 weeks intervals for the first 
3 months, and then continued every 4-6 weeks 
21 (100) - 7 (33)
AZA; 2-2.5 mg/kg/day - 15 (71) -
MTX; 15 mg/week - 1 (4) -
MMF; 2 g/day - 1 (4) -
RTX; 1 g/day every 6 months on two 
occasions at 2-week intervals
4 (19) - 2 (9)
Plasmapheresis 6 (28) - -
CYC: Cyclophosphamide, AZA: Azathioprine, MTX: Methotrexate, MMF: Mycophenolate mofetil, RTX: Rituximab.
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relation with mortality (p= 0.046, p= 0.022, and p= 
0.026, respectively). The prevalence of permanent 
dialysis was significantly lower in the patients that 
underwent plasmapheresis versus those did not 
(p= 0.047).
Two-, 5- and 11- year overall survival rates were 
91%, 86% and 82%, respectively. Mean survival was 
55.9 ± 42.8 (IR= 84.0) months. Survival analysis was 
performed, and estimated survival was 107.4 ± 10.9 
months.
DISCUSSION
The present study comprised the results of 11 years 
follow-up of GPA patients with diagnosis confirmed 
by tissue biopsies in a single tertiary hospital. URT 
involvement was associated with good prognosis, 
whereas cardiac involvement and renal failure 
requiring dialysis were associated with poor prognosis. 
However, no relationship was demonstrated between 
any of the other demographic, clinical or biological 
parametres and patient survival. Among patients with 
ESRF requiring dialysis, prevalence of dialysis 
dependency was significantly lower in the patients 
who received plasmapheresis than in those who did 
not (p< 0.047). The mean follow-up period was 43 
months with overall survival of 82%. The estimated 
survival was 107.4 ± 10.9 months.
In different studies, time to diagnosis from the onset 
of symptoms was reported to be 4.5-10.3 months 
(5-8). Abdou et al. reported that only 22% of the 
patients were diagnosed in the first month after the 
onset of symptoms, whereas the diagnosis was made 
within 6-12 months in 15% and after > 1 year in 18% 
of the patients (9). In the present study, mean time 
from the onset of symptoms to diagnosis was 7.8 
months. This slightly longer period was attributed to 
delayed presentation of the patients to our hospital. 
There were 11 cases (50%) diagnosed within 2 
months; of which four (18%) had been diagnosed 
within 1 month. Time to diagnosis was > 1 year (48 
months) in only one case. This case had isolated pul-
monary involvement, which was first considered to 
be tuberculosis. Reinhold-Keller et al. and Takala et 
al. pointed out that a multidisciplinary approach may 
reduce diagnostic delay in patients with suspicion of 
systemic vasculitis (10,11).
GPA is a potentially fatal disease with a life expec-
tancy of 5 months in untreated patients. One- and 
2- year mortality rates were 80% and 93%, respec-
tively (12). Concurrent use of CYC and corticosteroid 
therapy resulted in a rapid decrease in mortality 
(10,12,13), and 10-year survival rates reached to 
75%-88% (7,10). In the present study, four cases died 
during follow-up and 11-year survival rate was found 
to be 82%. Most of our cases (91%) lived longer than 
1 year. However, Mahr et al. described lower survival 
Figure 1. Survival time (A) in patients with upper respiratory tract involvement and (B) with end-stage renal failure requiring hemodialysis.
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rate (67.5% for 2-years) for GPA patients in his pro-
spective,  multicenter study (14). Selected patient 
population and nature of the studies may have contrib-
uted to the differences in survival rates. Mortality rates 
varied between 14% and 41% in different studies 
(5-7,10,14-16). In an early study from Turkey (2005), 
mortality rate was 41% in a mean 36-month follow-up 
period, and this higher rate of mortality was found to 
be related to the initial organ damage (6). A later study 
from Turkey (2010) determined the mortality rate to be 
20% in a mean 45-month follow-up period (15). In the 
present study, mortality rate was 18% in a mean 
43-month follow-up period. Reduction in mortality 
rates over the years, in our country, may be associated 
with increased awareness about the disease, enhanced 
diagnostic facilities, and the use of effective treatment 
methods.
Current strategy for induction of remission includes 
the use of high-dose corticosteroid together with CYC 
or RTX. Plasmapheresis can be performed in the 
patients with life-threatening organ involvement. RTX 
and CYC were compared in two large-scale studies 
(17,18) in the literature. While RAVE (Rituximab in 
Anti-neutrophil Cytoplasmic Antibody-Associated 
Vasculitis) study failed to demonstrate superiority of 
RTX to CYC in the induction of remission, better out-
comes were obtained with RTX in relapse disease 
(17). In the RITUXVAS study of The European 
Vasculitis Study Group (EUVAS), it was expressed 
that RTX is not superior to CYC but effective in the 
induction of remission (18). No difference was deter-
mined between the two drugs in terms of adverse 
events in either study. In the present study, RTX was 
used for the induction of remission in four and for 
relapse in two patients. The number of patients was 
not adequate to statistically compare the efficacy of 
CYC and RTX. Remission was achieved in all but one 
of the patients receiving RTX.
The protective effect of URT involvement in GPA was 
demonstrated in some studies (5,14,19). Luqmani et 
al. determined better prognosis in non-renal GPA 
patients, in whom URT involvement was more prev-
elant (19). In addition, two other studies suggested 
that the presence of URT disease may be associated 
with better outcome, which has been supported by 
the results of the present study (5,14). Relapse rate 
was reported to be higher in the patients with URT 
involvement (20). In the present study, the relapse 
rate was 41% and URT disease was detected in all 
patients that developed relapse. 
Although the effect of pulmonary involvement on 
survival has not been demonstrated in the majority of 
studies (6,7,14,16), Reinhold-Keller et al. reported 
that patients without pulmonary involvement live 
longer, independent of age and time to diagnosis 
(10). We were unable to show any effect of pulmo-
nary involvement and alveolar hemorrhage on sur-
vival. 
Renal involvement may present with different symp-
toms and signs including hematuria, proteinuria, ele-
vated creatinine level, and ESRF. The fact that renal 
involvement is a determinant of poor prognosis was 
demonstrated for the first time by Carrington and 
Liebow (21). This finding was supported by Luqmani et 
al. (19) However, the relation of renal involvement with 
poor prognosis could not be demonstrated in the pre-
sent study, as it was in some other studies (7,16). 
Nevertheless, confirming some earlier studies 
(6,7,14,22), ESRF requiring dialysis was a significant 
risk factor for mortality. ESRF requiring dialysis was a 
better determinant than serum creatinine level in the 
present study. Renal function was recovered in 64% 
(7/11) of the cases that received dialysis at baseline. 
Hence, the presence of ESRF requiring dialysis at base-
line does not indicate permanent renal injury. It has 
been demonstrated that addition of plasmapheresis to 
corticosteroids and CYC therapy, in the presence of 
renal failure, is associated with higher rates of renal 
recovery and dialysis independency in the first year 
(23). It probably has no effect on mortality or long-term 
renal functions (23). In the present study, there was a 
significant relation between plasmapheresis and dialy-
sis dependency. Dialysis independency developed in 
five, all of whom had received plasmapheresis, of the 
11 patients that required dialysis at baseline and sur-
vived > 3 months. Dialysis was continued throughout 
the follow-up period in the four (3 hemodialysis, 1 
peritoneal dialysis) of remaining six patients.
There was a significant increase in mortality in the 
patients with cardiac involvement (p< 0.026). One of 
the two patients with cardiac involvement died after 
6 months and the other after 5.5 months follow-up. 
One prior study demonstrated a significant relation 
between cardiac involvement and survival, but 
another two studies did not (5,7,10).
The present study had several limitations. Patient data 
until the last 4 years were obtained retrospectively 
from medical records. Despite the fact that patient 
records included necessary clinical, laboratory and 
pathological data, there may have been some inade-
Tuberk Toraks 2016;64(3):223-229
Şen N, Aydın Tufan M, Yıldız R, Ersözlü Bozkırlı ED, Yücel E. 
229
quacy because BVAS and VDI scores were retrospec-
tively calculated based on the records. Treatment-
related complications could not be assessed com-
pletely because of limited data. Nevertheless, non-
randomized treatments might have unfavorably influ-
enced our results. 
In conclusion, diagnosis of GPA may be delayed by 
the nonspecific nature of its symptoms. URT involve-
ment was associated with good prognosis, whereas 
cardiac involvement and ESRF requiring dialysis 
were associated with poor outcome. The present 
study supports the use of plasmapheresis in GPA 
patients with ESRF requiring dialysis. 
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